TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03873389

Intervention type: DRUG
Intervention: Ocrelizumab
Description: Patients who are beginning this medication based on patient's treating physician's recommendation will be enrolled in the study.
Study: NCT04347005

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cohort 1: AR882
Description: Single dose of AR882 or matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 2: AR882
Description: Single dose of AR882 or matching placebo
Study: NCT00929682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Randomization between two referenced treatments
Description: Levobupivacaine 0.568 mg.mL-1 and sufentanil 0.45 g.mL-1, 20 mL epidurally for induction, then by a patient-controlled regimen with 5-mL self-administered boli in addition to a continuous infusion of 5 mL.hr-1.~Same protocol, with levobupivacaine 1.136 mg.mL-1 and sufentanil 0.45 g.mL-1.

Intervention type: DRUG
Group type: OTHER
Intervention: Randomization between two referenced treatments
Description: Levobupivacaine 0.568 mg.mL-1 and sufentanil 0.45 g.mL-1, 20 mL epidurally for induction, then by a patient-controlled regimen with 5-mL self-administered boli in addition to a continuous infusion of 5 mL.hr-1.~Same protocol, with levobupivacaine 1.136 mg.mL-1 and sufentanil 0.45 g.mL-1.
Study: NCT01085097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Laquinimod
Description: Laquinimod will be administered per dose and schedule specified in the arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Laquinimod
Description: Laquinimod will be administered per dose and schedule specified in the arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Mycophenolate Mofetil (MMF) will be administered per dose and schedule specified in the arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Mycophenolate Mofetil (MMF) will be administered per dose and schedule specified in the arm description.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: Mycophenolate Mofetil (MMF) will be administered per dose and schedule specified in the arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone/Prednisone
Description: Prednisolone/Prednisone will be administered per dose and schedule specified in the arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone/Prednisone
Description: Prednisolone/Prednisone will be administered per dose and schedule specified in the arm description.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisolone/Prednisone
Description: Prednisolone/Prednisone will be administered per dose and schedule specified in the arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching to laquinimod will be administered per schedule specified in the arm description.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to laquinimod will be administered per schedule specified in the arm description.
Study: NCT04347005

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cohort 2: AR882
Description: Single dose of AR882 or matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 3: AR882
Description: Single dose of AR882 or matching placebo
Study: NCT01085097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Methylprednisolone (MP) will be administered per dose and schedule specified in the arm description.
Study: NCT04347005

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cohort 3: AR882
Description: Single dose of AR882 or matching placebo
Study: NCT04347005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 4: AR882
Description: Single dose of AR882 or matching placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cohort 4: AR882
Description: Single dose of AR882 or matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 5: AR882
Description: Single dose of AR882 or matching placebo
Study: NCT03310385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GHX02
Description: Herbal medicine originating from gualouhengryunhwan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GHX02
Description: Herbal medicine originating from gualouhengryunhwan

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets
Study: NCT03485196

Intervention type: OTHER
Intervention: Microsatellite instability
Description: The microsatellite instability status are definite to three type:MSI-H, MSI-L,and MSS. The gastric cancer patients who received D2 resection were included in 3 groups：MSI-H group， MSI-L group，and MSS group. All patient must be accept fluorouracil(5-FU) based adjuvant chemotherapy. We will analyze the relationship between MSI status and efficacy of 5-FU based adjuvant chemotherapy by observing the survival period of patients with different MSI status.

Intervention type: OTHER
Intervention: Microsatellite instability
Description: The microsatellite instability status are definite to three type:MSI-H, MSI-L,and MSS. The gastric cancer patients who received D2 resection were included in 3 groups：MSI-H group， MSI-L group，and MSS group. All patient must be accept fluorouracil(5-FU) based adjuvant chemotherapy. We will analyze the relationship between MSI status and efficacy of 5-FU based adjuvant chemotherapy by observing the survival period of patients with different MSI status.

Intervention type: OTHER
Intervention: Microsatellite instability
Description: The microsatellite instability status are definite to three type:MSI-H, MSI-L,and MSS. The gastric cancer patients who received D2 resection were included in 3 groups：MSI-H group， MSI-L group，and MSS group. All patient must be accept fluorouracil(5-FU) based adjuvant chemotherapy. We will analyze the relationship between MSI status and efficacy of 5-FU based adjuvant chemotherapy by observing the survival period of patients with different MSI status.
Study: NCT00488696

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endovascular Bifurcated Stent-Graft
Description: Treatment of Aneurysm involving the proximal aortic arch with endovascular bifurcated stent-graft.
Study: NCT01601262

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Intensity Extracorporeal Shock waves (Cardiospec 1000)
Description: We will apply the cardiospec 1000 unit for LI-ESWL in the penile and inguinal areas, 300 shocks per area, total of 1500 shocks. Full description of treatment series can be seen in the detailed protocol.
Study: NCT01085097

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylprednisolone
Description: Methylprednisolone (MP) will be administered per dose and schedule specified in the arm description.
Study: NCT03357692

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: all on four implant rehabilitation
Description: implant insertion after piezoelectric site preparation for trans-sinusal implants
Study: NCT02797847

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALN-TTRSC02
Description: Ascending doses of ALN-TTRSC02 by subcutaneous (SC) injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile Normal Saline (0.9% NaCl)
Description: Calculated volume to match active comparator
Study: NCT04735120

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iLASE DIODE LASERS
Description: 940nm diode laser with 1.5 watts activated in a continuous mode and applied on to the canal orifices during root canal treatment to reduce intraoperative pain and further its effect on post operative pain is assessed
Study: NCT04347005

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cohort 5: AR882
Description: Single dose of AR882 or matching placebo
Study: NCT00174655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicine + docetaxel sequential
Description: doxorubicin 75 mg/m² i.v. day 1, q 21 days for 3 cycles, followed by docetaxel 100 mg/m² i.v., 1 hour infusion, day 1, q 21 days for 3 cycles, followed by CMF for 3 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicine + cyclophosphamide sequential
Description: doxorubicin 75 mg/m² i.v. day 1 q 21 days for 4 cycles, followed by CMF (C: cyclophosphamide 100 mg/m² orally days 1-14, M: methotrexate: 40 mg/m² i.v. days 1 and 8, FU; 5-fluorouracil: 600 mg/m²) i.v. days 1 and 8, q 28 days for 3 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicine + cyclophosphamide combined
Description: doxorubicin 60 mg/m² i.v. + cyclophosphamide 600 mg/m² i.v., day 1, q 21 days for 4 cycles, followed by CMF for 3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicine + docetaxel combined
Description: doxorubicin 50 mg/m² i.v. + docetaxel 75 mg/m² i.v. 1 hour infusion (1 hour after doxorubicin), day 1, q 21 days for 4 cycles, followed by CMF for 3 cycles.
Study: NCT01060033

Intervention type: DEVICE
Group type: OTHER
Intervention: MR Spectroscopy

Intervention type: DEVICE
Group type: OTHER
Intervention: Fat-Saturation and Diffusion-Weighted Imaging

Intervention type: DEVICE
Group type: OTHER
Intervention: Dynamic Contrast Enhancement MRI (MR-DCE)

Intervention type: DEVICE
Group type: OTHER
Intervention: Diffusion Tensor Imaging (DTI)
Study: NCT04069156

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LVAD Implant
Description: Subjects will undergo Heartmate 3 LVAD implant prior to randomization

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: LVAD Implant
Description: Subjects will undergo Heartmate 3 LVAD implant prior to randomization
Study: NCT04347005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 6: AR882 Food Effect
Description: Single dose of AR882 or matching placebo in a fed state

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cohort 6: AR882 Food Effect
Description: Single dose of AR882 or matching placebo in a fed state
Study: NCT04069156

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 100mg
Description: Subjects will be randomized to either Placebo or Aspirin post implant.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Subjects will be randomized to either Placebo or Aspirin post implant
Study: NCT04347005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 7: AR882 Solid Oral Formulation
Description: Single dose of AR882 or matching placebo
Study: NCT01771432

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic treatment
Description: Kidney transplant recipients with asymptomatic bacteriuria will be treated with antibiotics

Intervention type: OTHER
Group type: OTHER
Intervention: No treatment
Description: Kidney transplant recipients with asymptomatic bacteriuria will be followed without antibiotic therapy
Study: NCT03676881

Intervention type: DEVICE
Intervention: Computerized cognitive battery: Cognigram (CG)
Description: is a validated, computerized battery of cognitive tasks based on card games, developed by Cogstate Ltd. This technology includes four tasks, with a total duration of 10-15 minutes. The subject is asked to answer each task by pressing either 'D' or 'K' keyboard buttons. The technology supports the measurement of attention/vigilance, processing speed, concentration, visual working memory and visual recognition memory. The software will run on a computer supplied by the Bruyère Research Institute, in a private test room. The RA will be present during the testing session, reading out loud the batteries standardized instructions and doing the practice trials with the participants. After the practice trials, the RA will not give any feedback or support.
Study: NCT04347005

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cohort 7: AR882 Solid Oral Formulation
Description: Single dose of AR882 or matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 8: AR882 in combination with allopurinol
Description: Single dose of allopurinol alone and a single dose of AR882 in combination with a single dose of allopurinol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cohort 8: AR882 in combination with allopurinol
Description: Single dose of allopurinol alone and a single dose of AR882 in combination with a single dose of allopurinol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 9: AR882 in combination with febuxostat
Description: Single dose of febuxostat alone and a single dose of AR882 in combination with a single dose of febuxostat
Study: NCT03676881

Intervention type: DEVICE
Intervention: Computerized cognitive battery: Cognigram (CG)
Description: is a validated, computerized battery of cognitive tasks based on card games, developed by Cogstate Ltd. This technology includes four tasks, with a total duration of 10-15 minutes. The subject is asked to answer each task by pressing either 'D' or 'K' keyboard buttons. The technology supports the measurement of attention/vigilance, processing speed, concentration, visual working memory and visual recognition memory. The software will run on a computer supplied by the Bruyère Research Institute, in a private test room. The RA will be present during the testing session, reading out loud the batteries standardized instructions and doing the practice trials with the participants. After the practice trials, the RA will not give any feedback or support.

Intervention type: DEVICE
Intervention: The NeuroCatch™ Platform (NCP)
Description: the NCP includes 6 stimulus sequences specifically designed to elicit desired brain responses. Each sequence contains both the oddball task and semantic word-pair task, and lasts 6 minutes. In our protocol, two sequences will be used. For the setup, EEG electrodes are placed on the participant's scalp, and the EEG signal quality is ensured by gently abrading the skin beneath each of the electrodes. A conductive gel is then placed between the skin and the electrode. Most electrodes are contained in an elastic cap, which is worn by the participants, but some electrodes are attached to the skin with adhesive. This part of the session takes around 10 minutes. EEG scan will commence once the setup is completed. Two auditory scans of 6 minutes each, separated by a one-minute break, will be administered. The total time of EEG testing for participants, including setup, will be of ≈25 minutes.
Study: NCT00504595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACZ885 (investigational)
Description: The ACZ885 was supplied in 6 mL colorless glass vials each containing nominally 150 mg ACZ885 (with 20% overfill). The vials were kept at 2-8°C. At the investigator's site, solutions for infusion were prepared depending on the volume and dose administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo of ACZ885 was supplied in the form of a lyophilized cake (Powder for Solution for Infusion). At the investigator's site, solutions for infusion were prepared depending on the volume and dose administered.
Study: NCT03676881

Intervention type: DEVICE
Intervention: The NeuroCatch™ Platform (NCP)
Description: the NCP includes 6 stimulus sequences specifically designed to elicit desired brain responses. Each sequence contains both the oddball task and semantic word-pair task, and lasts 6 minutes. In our protocol, two sequences will be used. For the setup, EEG electrodes are placed on the participant's scalp, and the EEG signal quality is ensured by gently abrading the skin beneath each of the electrodes. A conductive gel is then placed between the skin and the electrode. Most electrodes are contained in an elastic cap, which is worn by the participants, but some electrodes are attached to the skin with adhesive. This part of the session takes around 10 minutes. EEG scan will commence once the setup is completed. Two auditory scans of 6 minutes each, separated by a one-minute break, will be administered. The total time of EEG testing for participants, including setup, will be of ≈25 minutes.
Study: NCT03207932

Intervention type: PROCEDURE
Intervention: Central vein catheterisation
Description: ultrasound guided versus landmark central vein catheterisation

Intervention type: PROCEDURE
Intervention: Central vein catheterisation
Description: ultrasound guided versus landmark central vein catheterisation
Study: NCT04253288

Intervention type: OTHER
Group type: OTHER
Intervention: Morbidity Mortality Review (MMR)
Description: * Standardization of Morbidity Mortality Review (MMR) in radiotherapy centers~* National database from MMR board meetings which include clinical , radiation technique and biological parameters of intrinsic radiosensitivity of patients
Study: NCT00764530

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alumina/Alumina
Description: CeramTec Acetabular Alumina Insert and CeramTec Alumina head used with Foundation Porous Coated Acetabular Shell
Study: NCT04347005

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cohort 9: AR882 in combination with febuxostat
Description: Single dose of febuxostat alone and a single dose of AR882 in combination with a single dose of febuxostat
Study: NCT01381549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2251052
Description: Reconstituted, added to 250mL 0.9% NaCl solution and administered via IV infusion
Study: NCT00764530

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard
Description: Foundation Porous Coated Acetabular Shell with Polyethylene Insert with the CeramTec Alumina head
Study: NCT02736045

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: emWave
Description: Our approach will be to test the impact of this intervention through a smartphone application, emWave software, which will be provided to all our subjects. emWave is a tool that reduces stress by allowing individuals to be less reactive, think clearly, and make good decisions, especially under pressure. Fifty medical residents with high burnout symptoms will be randomized to receive an 8-week intervention (emWave - computer based resilience training program).
Study: NCT01678417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 131I-rituximab
Study: NCT01376271

Intervention type: DRUG
Intervention: Paroxetine
Study: NCT02532296

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transition Coach (TC)
Description: TC reviews patient's medical record to understand current admission and the medical/psycho-social history. TC makes introductory hospital visit(s) with patient to establish rapport and to define post-discharge needs.~Starting in-house and continuing after discharge, TC helps patient set transition goals to maximize healthcare outcomes. Post-discharge, TC offers a voluntary face-to-face visit with patient along with weekly outreach calls, which are designed to assist patient with goal setting and attainment, medical system navigation; medication management; medical follow-up; transportation; use of community resources; and self-care.~Intervention lasts 30 days post-discharge; afterwards TC seeks to handoff to an outpatient care team member, to ensure continuity of care.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Receives usual hospital-based care, discharge preparation, transitional care and outpatient care.
Study: NCT03617081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0113-2023
Description: Participants will receive dose levels of 1 mg, 2 mg, 4 mg, 8 mg, 16 mg or 32 mg of NNC0113-2023 orally. Each participant will receive only one dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (NNC0113-2023)
Description: Participants will receive NNC0174-0833 matched placebo orally.
Study: NCT02074995

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BVS857
Description: Group 1A\&1B receive first dose as IV then remaining doses as SC. Groups 2, 3 and 4 receive only SC doses.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BVS857
Description: Group 1A\&1B receive first dose as IV then remaining doses as SC. Groups 2, 3 and 4 receive only SC doses.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Group 1B receive first dose as IV then remaining doses as SC. Groups 2, 3 and 4 receive only SC doses.
Study: NCT03784885

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AD07010
Description: A protein based adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AD07010
Description: A protein based adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated trivalent influenza vaccine
Description: Inactivated trivalent seasonal influenza vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated trivalent influenza vaccine
Description: Inactivated trivalent seasonal influenza vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated trivalent influenza vaccine
Description: Inactivated trivalent seasonal influenza vaccine
Study: NCT00844363

Intervention type: PROCEDURE
Group type: OTHER
Intervention: NB-UVB
Description: UVB light will be administered to the entire body except for the genitals in men and eyelids, which will be shielded.NB-UVB dosing is increased by 5-20% increments in exposure time, depending on response of the patient.
Study: NCT02154191

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Intervention
Description: The clinical intervention in this study is the routine surgical procedures taken for patients requiring surgery for degenerative lumbar spinal stenosis.
Study: NCT01708174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDE225
Description: Sonidegib for oral suspension was supplied in amber glass bottles. Sonidegib oral suspension was combined with the supplied reconstitution vehicle to a final concentration of 50 mg/mL.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TMZ
Description: Temozolomide capsules were obtained locally by the Investigator
Study: NCT00974012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Divalproex Sodium
Description: 500 mg ER Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Depakote®
Description: 500 mg ER Tablet
Study: NCT00426582

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Patupilone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patupilone
Study: NCT03668626

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Family-centered intervention program (FCIP)
Description: This program included in-hospital intervention, after-discharge intervention and neonatal follow-up. Five sessions of in-hospital intervention emphasized modulation of the NICU, teaching of child developmental skills, feeding support, massage, interactional activities and parent support and education. The 7-session after-discharge intervention consisted of 4 clinic visits and 3 home visits with specific care in modulation of home environment, teaching of child developmental skills, feeding support, teaching of interactional activities, and parent support and education.